FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA® is the only SGLT2 inhibitor with UK-specific real world evidence from the CPRD database3

Patients in the UK initiated on FORXIGA® with metformin:

  • Experienced an average reduction in HbA1c of more than 1.1 % when treated for 6 months or longer with FORXIGA®3
  • Results from real-world evidence studies may not necessarily relate to the effect of the intervention/treatment alone. Results should be interpreted in the context of randomised controlled trial findings.

What is CPRD?

  • CPRD stands for Clinical Practice Research Datalink29
  • A governmental, not-for-profit research service, jointly funded by the NHS National Institute for Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA)29
A database of 12,000,000 patient records
A database of 12,000,000 patient records

Study inclusion criteria and definition of treatment groups3

Study inclusion criteria and definition of treatment groups
Study inclusion criteria and definition of treatment groups

 

*Creatinine clearance < 60 ml/min or estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2.3
**Insulin ≤3 months prior to FORXIGA® initiation and ≤3 months post FORXIGA® initiation.3